Literature DB >> 7073267

Pharmacokinetics of cefadroxil after oral administration in humans.

F La Rosa, S Ripa, M Prenna, A Ghezzi, M Pfeffer.   

Abstract

The human oral pharmacokinetics of cefadroxil were studied in parallel at doses of 250, 500, and 1,000 mg in three groups of 10 healthy young male volunteers. Renal excretion of intact cefadroxil, accounted for 82, 79, and 77% of the above doses. Mean peak serum levels were dose linear: 9, 18, and 35 microgram/ml at 250, 500, and 1,000 mg, respectively. However, overall pharmacokinetics were linear only in the 250- to 500-mg dose range; apparent serum clearances were 10 liters/h, and true renal clearances were 9 and 8 liters/h at 250 and 500 mg. At 1,000 mg, apparent serum clearance dropped to about 7 liters/h, true renal clearance, dropped to 6 liters/h, and the area under the curve increased disproportionately. At 250 and 500 mg, mean half-life was about 1.2 h; at 1,000 mg, however, it was 1.6h. The nonlinear decrease in clearance could be related to saturation of active renal tubular secretion of cefadroxil between the 500- and 1,000-mg doses. Previous results indicating that cefadroxil has greater persistence than other oral cephalosporins such as cephalexin, cephradine, cefaclor were confirmed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7073267      PMCID: PMC181879          DOI: 10.1128/AAC.21.2.320

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency.

Authors:  G Humbert; A Leroy; J P Fillastre; M Godin
Journal:  Chemotherapy       Date:  1979       Impact factor: 2.544

2.  Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine.

Authors:  M Pfeffer; A Jackson; J Ximenes; J P de Menezes
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

3.  [Pharmacokinetics of cefadroxil, a new oral cephalosporin (author's transl)].

Authors:  C Simon
Journal:  Arzneimittelforschung       Date:  1980

4.  Laboratory studies with BL-S 578 (Cefadroxil) a new broad-spectrum orally active cephalosporin.

Authors:  S Ripa; M Prenna
Journal:  Chemotherapy       Date:  1979       Impact factor: 2.544

5.  [Comparative pharmacokinetics of oral cephalosporins: cephalexin, cefaclor and cefadroxil (author's transl)].

Authors:  H Lode; R Stahlmann; G Dzwillo; P Koeppe
Journal:  Arzneimittelforschung       Date:  1980

6.  Cefadroxil, a new broad-spectrum cephalosporin.

Authors:  R E Buck; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

  6 in total
  7 in total

1.  Dose-dependent absorption and elimination of cefadroxil in man.

Authors:  T M Garrigues; U Martin; J E Peris-Ribera; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2013-11       Impact factor: 4.200

3.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Population pharmacokinetic modeling of cefadroxil renal transport in wild-type and Pept2 knockout mice.

Authors:  Yehua Xie; Hong Shen; Yongjun Hu; Meihua Rose Feng; David E Smith
Journal:  Xenobiotica       Date:  2015-09-15       Impact factor: 1.908

5.  Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

6.  Efficacy of a twice-daily regimen of cefadroxil in the treatment of respiratory tract infections.

Authors:  R Quintiliani
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia.

Authors:  M J Blaser; B D Klaus; J A Jacobson; E Kasworm; F M LaForce
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.